Lionco Pharmaceutical Group Co.,Ltd.

603669

CNE1000022R8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
5.07 ^CNY	+1.20%		+1.00%	-8.32%

Apr. 19	Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Jan. 31	Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	CI

Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.

January 02, 2024

From October 1, 2023 to December 31, 2023, the company has repurchased 8,491,700 shares, representing 1.13% for CNY 48.35 million. With this, the company has completed the repurchase of 8,491,700 shares, representing 1.13% for CNY 48.35 million under the buyback announced on January 31, 2023.

Latest news about Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	Jan. 30	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on January 31, 2023, has closed with 8,785,900 shares, representing 1.22% for CNY 50 million.	Jan. 27	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	Jan. 02	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	Nov. 13	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	Nov. 13	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	Nov. 13	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-20	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Lionco Pharma Registers Latamoxef Sodium for Injection in China	23-08-04	MT
Lionco Pharma's Bacterial Drug Passes Regulator's Evaluation	23-06-21	MT
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
Lionco Pharma Unit's Aztreonam for Injection Passes Drug Regulator's Evaluation	23-04-18	MT
Lionco Pharma to Raise Up to 100 Million Yuan Through Share Buyback	23-01-31	MT
Lionco Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	23-01-30	CI
Lionco Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	23-01-28	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	23-01-10	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on March 10, 2022 has closed with 8,915,893 shares, for CNY 60 million.	23-01-08	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	23-01-05	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	22-10-10	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	22-07-04	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI

Chart Lionco Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Lionco Pharmaceutical Group Co.,Ltd.

More charts

Company Profile

Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.

Sector

Pharmaceuticals

Calendar

2024-06-14 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LIONCO PHARMACEUTICAL GROUP CO.,LTD.	-8.32%	486M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.43%	42.25B
OTSUKA HOLDINGS CO., LTD.	+16.39%	21.27B
SANDOZ GROUP AG	+16.67%	15.23B
CIPLA LIMITED	+19.84%	14.36B
ZYDUS LIFESCIENCES LIMITED	+51.59%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.12%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B